Search
ivacaftor
Indications:
- cystic fibrosis patients with at least 1 CFTR mutation G551D
- used in combination with lumacaftor for treatment of cystic fibrosis CFTR F508del mutation [2]
Dosage:
- 150 mg PO every 12 hours
Mechanism of action:
- CFTR potentiator
General
pulmonary agent
heterocyclic compound, 1 ring
amide
phenol
Database Correlations
PUBCHEM cid=16220172
References
- Ramsey BW et al.
A CFTR potentiator in patients with cystic fibrosis and
the G551D mutation.
N Engl J Med 2011 Nov 3; 365:1663.
PMID: 22047557
- Davis PB.
Therapy for cystic fibrosis - The end of the beginning?
N Engl J Med 2011 Nov 3; 365:1734.
PMID: 22047565
- FDA News Release. July 2, 2015
FDA approves new treatment for cystic fibrosis
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm
Component-of
elexacaftor/ivacaftor/tezacaftor
ivacaftor/lumacaftor (Orkambi)
ivacaftor/tezacaftor